HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Not To Cross FTC: Attorneys Offer Advice For Cosmeceutical Marketers

This article was originally published in The Rose Sheet

Executive Summary

Claims for cosmeceuticals referred by the National Advertising Division go to the same place on the Federal Trade Commission's list of priorities as other disputed claims - straight to the top

You may also be interested in...



FDA Reels In Golden Caviar For Fishy Skin-Care Claims

Skin-lightening claims appear to be on FDA's radar as it continues its crackdown on overreaching cosmetic marketing, issuing a warning letter to Golden Caviar Skin Care for statements promoting a whitening serum and cream, among other offerings. The company's Caviar Lifting and Firming Serum with Zinc also is an unapproved drug, based on claimed benefits including wound healing and acne relief, the agency says.

FDA Serves Up More Warnings: Avon Cited For Touting Druglike Benefits

Claims cited in FDA’s warning to Avon Products Inc. include statements suggesting collagen-building and wrinkle-plumping benefits, as well as comparisons to in-clinic injections and the assertion that technology in the firm’s Anew Reversalist products can help “reactivate skin’s repair process to recreate fresh skin.” Avon has 15 days to reply.

GSC Digs Deep For Ingredients: Spices, Bacteria And Worm Excrement

Earthworm castings are a mainstay on organic farms for extending the life cycle of plants, but only now is the ingredient being used in skin care, touted to promote healthy stem cells.

Related Content

UsernamePublicRestriction

Register

RS015539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel